Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 5/20 | 0.50 |
| ▸ | LTB4R2 | Q9NPC1 | 4/20 | 0.50 |
| ▸ | MLYCD | O95822 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.44 |
| ▸ | ESRRG | P62508 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL206739 | 0.89 | LTB4R (0.52) | LTB4RLTB4R2MLYCDALDH1A1MAPT | |
| SCHEMBL13181407 | 0.89 | LTB4R (0.56) | LTB4RLTB4R2MLYCDALDH1A1MAPT | |
| SCHEMBL205522 | 0.86 | CHRNB2 (0.51) | MLYCDALDH1A1MAPTHPGDHDAC1 | |
| SCHEMBL23291183 | 0.86 | LTB4R (0.54) | LTB4RLTB4R2MLYCDALDH1A1ESRRG | |
| SCHEMBL13683271 | 0.84 | LTB4R (0.52) | LTB4RLTB4R2MLYCDALDH1A1NPY5R | |
| SCHEMBL3863448 | 0.84 | LTB4R (0.52) | LTB4RLTB4R2MLYCDALDH1A1MAPT | |
| SCHEMBL8233693 | 0.82 | LTB4R (0.50) | LTB4RLTB4R2MLYCDALDH1A1NPY5R | |
| SCHEMBL3859118 | 0.82 | LTB4R (0.50) | LTB4RLTB4R2MLYCDALDH1A1NPY5R | |
| SCHEMBL7367495 | 0.81 | ALDH1A1 (0.58) | ALDH1A1MAPTHPGDHDAC1LMNA | |
| SCHEMBL14357352 | 0.81 | LTB4R (0.52) | LTB4RLTB4R2MLYCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088760-B2 | Benzoxazole carboxamide inhibitors of poly(ADP-ribose)polymerase (PARP) | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-2247600-A2 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | Lead Therapeutics, Inc. (US) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009099736-A2 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090197863-A1 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197863-A1 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP2, PARP11 | LTB4R 2344/4885LTB4R2 2675/4885MLYCD 1675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.